• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$14.59 -$0.04 (-0.27%)

REAL-TIME: Last trade at

WuXi PharmaTech (Cayman), Inc....

NYSE:WX

WuXi PharmaTech Beats on Both Top and Bottom Lines

WuXi PharmaTech (Cayman) Beats on Both Top and Bottom Lines

ADR Report: Shares Up As Investors Shrug Off Euro Fears

Covidien Spins Off Drug Company: 5 Drug Makers Hedge Funds Want Most

Covidien Spins Off Drug Company: 5 Drug Makers Hedge Funds Want Most

Earnings Season: 10 Companies on Next Week's Roster Undervalued by Their Target Prices

WuXi PharmaTech Shares Popped: What You Need to Know

The 9 Top Value-Creating Life Sciences Companies

Can Chinese Biotech Appropriately Diversify Your Portfolio?

WuXi PharmaTech Beats Estimates on Strong Contract Manufacturing Numbers

Contract Research (CROs): On the Brink of Recovery

12 Stocks With Bearish Momentum Being Sold by Mutual Funds

Benefit by Imitating Julian Robertson: Bullish on Commodities, China, And Tech

WuXi PharmaTech on the Right Track With 24% Growth in Revenues

Top 30 Most Undervalued, Underperforming Stocks

Contrarian Ideas: 19 Deeply Undervalued, Beaten Up Stocks

Growth Stocks That Analysts Love

29 BRIC Stocks With Growth Potential

Analyst Calls: CLR, CSIQ, DD, DE, DECK, EMC, EMN, WFMI, WWW ...

Analyst Calls: BRCD, CCE, DPS, HOV, JOYG, KMB, KO, PEP, S, ...

China Biotech Week in Review: VC Investment to Hit New High in 2010

WuXi PharmaTech Reports Outstanding Q3, Raises Full-Year Guidance

ShangPharma's IPO: Priced About Right for the Short Term

Big Pharma Begins Outsourcing Research and Development

Think Healthcare Ahead of China's 12th Five-Year Plan

WuXi PharmaTech Subsidiary Wins ISO Environmental Certification

China Biotech Week in Review: New IPO

Chinese Reverse Merger Stocks: Closing the Gap With IPOs

China Biotech Week in Review: More Support for Biopharma

WuXi's Plans for New R&D Center Show No Lack of Capital Following Charles River Breakup

Qiagen Hopes to Double China Revenues in 2010

China Biotech in Review: Orthopedic Device Maker Plans NYSE Debut

Where Does the WuXi Deal Breakup Leave Charles River?

Quarterly Results Suggest Charles River May Have Missed Big With Wuxi

Analyst Calls: AMAT, AZO, GVA, HBC, IRE, NWL, OXY, VVUS, WX ...

WuXi CEO Blames Short-Term Financial Concerns for Merger's Demise

Charles River Investors Kill WuXi Deal

Wall Street Breakfast: Must-Know News

Charles River and WuXi Merger: Sum Is Greater Than the Parts

UPDATE 1-WuXi Pharma Q1 profit beats estimates, appoints new CFO

See More Articles...